Kiora Pharmaceuticals, Inc.(NASDAQ : EYEG)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.60%||163.54||0.7%||$1305.95m|
|LLY||Eli Lilly & Co.||-1.93%||323.65||1.1%||$1056.02m|
|BMY||Bristol-Myers Squibb Co.||-0.82%||71.12||1.0%||$763.08m|
|MRK||Merck & Co., Inc.||-0.52%||86.19||0.7%||$687.90m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-4.41%||200.16||8.2%||$210.64m|
|GBT||Global Blood Therapeutics, Inc.||0.04%||68.10||5.4%||$190.73m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||-0.21%||151.22||0.0%||$178.64m|
|IDXX||IDEXX Laboratories, Inc.||-1.81%||325.80||3.9%||$175.84m|
|HZNP||Horizon Therapeutics Plc||-1.28%||61.89||5.4%||$160.55m|
|NVO||Novo Nordisk A/S||-0.74%||99.65||0.1%||$140.44m|
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Salt Lake City, UT.